GlycoMimetics to Present at Jefferies 2018 Global Healthcare Conference
June 01 2018 - 4:15PM
Business Wire
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that Chief
Executive Officer Rachel King will provide a company overview at
the Jefferies Annual Health Care Conference in New York, on
Thursday, June 7, 2018, at 11:30 a.m. ET.
To access the live webcast and subsequent archived recordings
for the presentation, please visit
the GlycoMimetics website
at www.glycomimetics.com.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company
focused on the discovery and development of novel glycomimetic
drugs to address unmet medical needs resulting from diseases in
which carbohydrate biology plays a key role. GlycoMimetics' most
advanced drug candidate, rivipansel, a pan-selectin antagonist, is
being developed for the treatment of vaso-occlusive crisis in
sickle cell disease and is being evaluated in a Phase 3 clinical
trial being conducted by its strategic collaborator, Pfizer.
GlycoMimetics' wholly-owned drug candidate, GMI-1271
(uproleselan), an E-selectin antagonist, was evaluated in a Phase
1/2 clinical trial as a potential treatment for AML and is
currently being evaluated in a Phase 1 clinical trial for the
treatment of multiple myeloma. The FDA granted GMI-1271
Breakthrough Therapy designation for the treatment of adult
AML patients with relapsed/refractory disease.
GlycoMimetics is also conducting a Phase 1 clinical trial with
a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin
antagonist. GlycoMimetics is located in Rockville,
MD in the BioHealth Capital Region. Learn more
at www.glycomimetics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180601005786/en/
GlycoMimetics, Inc.Investor Contact:Shari Annes,
650-888-0902sannes@annesassociates.comorMedia Contact:Jamie
Lacey-Moreira, 410-299-3310jamielacey@presscommpr.com
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Mar 2024 to Apr 2024
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Apr 2023 to Apr 2024